The trial is being done for cognitive disorders in Alzheimer’s and Schizophrenia
Suven Life Sciences’ NCE SUVN-D4010 has commenced phase I clinical trial in the US. SUVN-D4010 is a potent, selective, brain penetrant and orally active 5-HT4 receptor partial agonist for the treatment of cognitive dysfunction associated with Alzheimer’s disease and other dementias. Suven submitted Investigational New Drug Application (IND) to US FDA to conduct Phase-1 clinical trial for Cognition in Alzheimer’s disease, under 505(1) of the Federal Food, Drug and Cosmetic Act (FDCA) which was assigned an IND number 126099.
Based on the IND# 126099, “A single centre, double-blind, placebo-controlled, randomised, Phase I study to evaluate the safety, tolerability, and pharmacokinetics of SUVN-D4010 after single ascending doses and multiple ascending doses in healthy male subjects” for cognition in Alzheimer’s disease is underway in the US.
“We are pleased that the third compound from our pipeline of molecules in CNS has moved into clinical trial that is being developed for cognitive disorders in Alzheimer’s and Schizophrenia, a high unmet medical need which has huge market potential globally,” says Venkat Jasti, Chief Executive Officer, Suven.